Replies to post #35611 on Biotech Values

[DewDiligence]

> GENR PR: "Because most anti-angiogenic therapies that inhibit all VEGF pathways also inhibit the beneficial effects of eNOS, these findings underscore the fact that EVIZON exerts activity through specific anti-angiogenic and inflammatory signaling pathways, making it a truly novel member of this class."<

This is a modified version of OSIP’s failed thesis for Macugen. It won’t fool anyone except a few daytraders.

[masterlongevity]

let me summarize..

Even though our product does not work, it is safe. The other products on the market work well and they are safe too. Please help us.